Anti-VEGF therapy as adjuvant therapy: Clouds on the horizon?

Bryan P. Schneider, George W. Sledge

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

Original languageEnglish (US)
Article number303
JournalBreast Cancer Research
Volume11
Issue number3
DOIs
StatePublished - May 18 2009

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this